125849-86-7

Basic information

• Product Name: Silane, (1,1-dimethylethyl)diphenyl(3-thienylmethoxy)-
• CAS NO: 125849-86-7
• Molecular Formula: C21H24OSSi
• Molecular Weight: 352.572
• Mol File: 125849-86-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Silane, (1,1-dimethylethyl)diphenyl(3-thienylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Silane, (1,1-dimethylethyl)diphenyl(3-thienylmethoxy)-(125849-86-7)
• EPA Substance Registry System: Silane, (1,1-dimethylethyl)diphenyl(3-thienylmethoxy)-(125849-86-7)

Safety Data

• Hazardous Substances Data: 125849-86-7(Hazardous Substances Data)

Upstream product

• 71637-34-8 3-hydroxymethyl-thiophene 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 117657-67-7 [2-(tert-Butyl-diphenyl-silanyl)-thiophen-3-yl]-methanol 

Downstream Products

• 223254-19-1 4-((tert-butyldiphenylsilyloxy)methyl)thiophene-2-carbaldehyde 
• 117657-67-7 [2-(tert-Butyl-diphenyl-silanyl)-thiophen-3-yl]-methanol 
• 223254-21-5 1-[4-(tert-butyl-diphenyl-silanyloxymethyl)-thiophen-2-ylmethyl]-4-(2-isopropoxy-phenyl)-piperazine 
• 223254-23-7 {5-[4-(2-isopropoxy-phenyl)-piperazin-1-ylmethyl]-thiophen-3-yl}-methanol 

Relevant articles and documents

QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS

The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS

The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

Heterocycles useful in the treatment of benign prostatic hyperplasia

This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the α-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.